Under the Paperwork Reduction Act of 1995, no persons are required to resp

U.S.PATENTS

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	

Application Number		10809637
Filing Date		2004-03-24
First Named Inventor	Jun F	eng
Art Unit		1624
Examiner Name Habte		, Kahsay
Attorney Docket Numb	er	DPP4-5004-C2

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	Releva		Lines where ges or Relev		
	1	6998502		2006-02	P-14	Muhammed M					
	2	7230000		2007-06	i-12	Jeffrey T.Finer					
	3	7304086		2007-12	-04	Stephan Schill					
	4	7371871		2008-05	i-13	Stephan Schilling et al.					
If you wis	h to a	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applica of cited Document				Lines where ges or Relev	
	1	20050261319		2005-11	I-2 4	Ulrich Deuschi					
If you wis	h to a	d additional U.S. Publi:	shed Ap	plication	citatio	n information p	olease click the Ad	d button.	Add		_
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	or v	here Rel	or Relevant	T+	

	Application Number		10809637		
	Filing Date		2004-03-24		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Jun Fe		eng		
(Not for submission under 37 CFR 1.99)	Art Unit		1624		
(Not for Submission under or or it issue	Examiner Name	Habte	, Kahsay		
	Attorney Docket Number		DPP4-5004-C2		

1	EP 0748800	EP	1996-12-18	F, HOFFMANN-LA ROCHE AG	
2	WO 01/55119	wo	2001-08-02	NEUROCRINE BIOSCIENCES, INC.	
3	EP 1229024	EP	2002-08-07	Meiji Seika Kaisha, Ltd.	
4	EP 1398032	EP	2004-03-17	PheneX Pharmaceuticals AG	
5	WO 04/062613	wo	2004-07-29	BRISTOL-MYERS SQUIBB COMPANY	
6	WO 05/095381	wo	2005-10-13	SYRRX, INC.	
7	EP 1586571	EP	2005-10-19	Takeda Pharmaceutical Company Limited	
8	WO 07/033350	wo	2007-03-22	Takeda Pharmaceutical Company Limited	
9	WO 07/033266	wo	2007-03-22	Takeda Pharmaceutical Company Limited	
10	WO 07/033265	wo	2007-03-22	Takeda Pharmaceutical Company Limited	
11	EP 1407774 A1	EP	2004-04-14	LION biosciences AG	

			Attor	ney Doc	ket Number		DPP4-5004-C2			
	12	WO 04/024161	Wo		2004-03-25	u	ION biosciences AG			
	13	WO 04/024162	wo		2004-03-25		thenex Pharmaceuticals G			
If you wis	h to a	d additional Foreign P			, , , , , , , , , , , , , , , , , , ,					
			NON-PATE	NT LITE	ERATURE DO	CL	JMENTS	Remove		
Examiner Initials*	Cite No		nal, serial, sym	posium,	catalog, etc),		e article (when approptie, pages(s), volume-is		Τŝ	
	1	Alagarsamy, V. et al. "Synthesis and pharmacological investigation" Pharmazie, vol. 57, no. 5 2002, pages 306-307, XP000804498								
	2	Algarsamy, V. et al. "Synthesis, analgesis, anti-inflammatory" Bio & Pharm. Builetin of Japan, Pharma society of JP. vol. 25, no. 11, 2002, pp 1432-1435, XP08094513 ISSN: 0918-8158								
	3	Banker, G. et al. Modern Pharmaceutics, 3rd Edition, Marcel Dekker, New York. 1996, pp 451-596								
	4	Chemical Abstracts, vol. 65, no. 9, 1976, Columbus, Ohio, abstract No. 6245n E. BELGODERE, ELENA et al., "Synthesis of Substituted Pynnridines" XP:002296337								
	5	Desai N C et al "Synthesis and anti-Hiv" Indian Journal of Experimental Bio., vol. 36, no. 12, 1989 pages 1280-1283, XP008094596 ISSN 0019-5899								
	6	Green et al. Expert Opin. Emergin Drugs, 11(3); 525-539, 2006								
	7	Karnata et al., CAPLUS Abstract 105: 191027, 1986 Chemical & Pharma Bulletin (1985), 33(8), 3160-75								

8	Kotan; T. et al., "Highly selective aldose reductase" Journal of Medicinal Chem., American Chem. Society. Washington, US, Vol. 40, No. 5, 1997, pp 884-894 XP0006S2330	
9	Lin et al., CAPLUS Abstract 104:65665, 1986 Journal of Medicinal Chem. (1986) , 29(1), 84-9	
10	Mall et al. Reactivity Difference of Cis-Trans Pairs: Different Behavior of Stillbene Oxides and Activates Stilbene Imines, 1987, Jornal of Organic Chemistry, 52, 4812.	
11	Marcus et al. PubMed abstract (mierviirology, 45(4-6) pp. 260-6 (2002)	
12	Misra, V. et al. "Syntheses of N-aryl-n" Pol. J. Pharmacol Pharm vol. 31, 1979, pages 161-167, XP008084507	
13	Miyamura, K. et al. "Reaction of Copper (II) Complexes Optically" J. Chem. Soc. Delhon Trans. 1987, pp 1127-1132, XP008082357	
14	Sammour et al. Egyptian Journal of Chemistry (1979), Volume Date 1976, 19(6), 1109-16. (abstract 2 pages)	
15	Schilling et al., CAPLUS 2005:1050865 DN 143:347172	
16	Van Heeswijk et al. PubMed Abstract (Antiver Ther. 8(4):201-29) Dec 2001.	
17	Vppaguta et al., Advanced Drug Delivery Reviews 48: 3-26, 200	
18	W. Manfred E. "Burger's Medicinal Chem., Sed, Part 1, John Wiley & Sons, 1995, pp 975-977	

20 West, A. R. et al. "Solid State Chem and Applications, Wiley, New York, 1988, pages 358-8 365.		19	Wang et al. 'Studies of Quinazolinones' Borganic & Med hem., Letters, Oxford, GB, vol. 12, no. 4, 2002, pp 571-574, XP005077456 ISSN 0560-864X	
		20	West, A. R. et al. 'Solid State Chem and Applications, Wiley, New York, 1988, pages 358-& 365.	

EXAMINER SIGNATURE

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at www.USPTO.SCM2 or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patient documents, his addication of the year of the respon of the Emperer must preced the serial number of the patient document. ³ For the Comment of the patient document was set of the control of the patient document. ⁴ For the Document of the Symbol Document of The Symbol Document ⁴ Application ST. ⁴ Explosion ST. ⁴ E